What Ультралан Treats: Main Uses and Benefits

Ультралан (Fluocortolone) is utilized in conditions where additional symptomatic support is needed for inflammation.

Quick Fact: Relief for Acute Discomfort

Ультралан is relevant when short-term symptomatic assistance is needed in acute inflammatory conditions where symptoms interfere with daily comfort. This supportive role helps patients cope more steadily with difficult episodes.

The medication is commonly used across conditions characterized by periods of heightened symptoms, which may include manifestations of eczema, dermatitis flare-ups, and the symptomatic burden associated with hemorrhoidal disease. It helps address symptom clusters that may become intense or disruptive, such as visible redness, swelling, scaling, and intense localized itching (pruritus).

In anorectal inflammatory conditions, the medication is used for managing symptoms that may become intense, such as painful swelling and burning associated with hemorrhoidal disease, and is relevant in contexts like proctitis or anal fissures. By easing distress, this medication supports patients during difficult episodes and helps reduce generalized discomfort in the affected area.

Overall Benefit: Ультралан contributes to improved day-to-day comfort and helps maintain a sense of stability when symptoms are more noticeable, assisting with maintaining functional stability during symptomatic periods.

Official Eligibility and Non-Eligibility Status

Ультралан (Fluocortolone) is approved for use in the general adult population for short-term, localized application under standard conditions. However, regulatory documents establish specific populations for whom the medicine is contraindicated or its use is restricted.

Classification	Population/Condition	Restriction Details
Contraindicated	Hypersensitivity	Patients with known allergy to Fluocortolone or its excipients must not use it.
Contraindicated	Localized Infections	Use is prohibited in the presence of viral diseases (e.g., herpes simplex), tuberculous, or syphilitic processes in the area to be treated.
Conditional Use	Bacterial/Fungal Infections	Must not be used unless an appropriate specific antimicrobial or antimycotic therapy is administered concurrently.
Not Recommended	Pregnancy (First Trimester)	Use of potent topical corticosteroids is generally not recommended during the first trimester.
Restricted Use	Infants/Children	Long-term continuous therapy must be avoided due to the higher risk of systemic absorption. The duration of treatment should generally not exceed 1 week for all populations.

Regulatory basis: Eligibility status and prohibitions are defined by official government documents, which determine the necessity of avoiding systemic absorption risks and preventing the spread of underlying infections.

Interactions with other medicines and products

The interaction profile for Fluocortolone (found in Ультралан) is primarily defined by the potential for medicines to increase its systemic concentration and its inherent capacity for additive biological effects with co-administered agents. Although applied locally, systemic absorption can occur, making specific interactions relevant according to regulatory documents.

Pharmacokinetic and Contraindicated Combinations

The most significant interaction is pharmacokinetic, involving the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with strong CYP3A4 inhibitors reduces the metabolic clearance of Fluocortolone, resulting in an officially documented increase in systemic exposure.

Classification	Interacting Agents
Formally Contraindicated	Ritonavir and Cobicistat
Mechanism	Reduced clearance; Increased systemic exposure

Pharmacodynamic Interactions

Pharmacodynamic interactions arise from the additive physiological effects of Fluocortolone's glucocorticoid properties:

• Anti-diabetic medicines: Fluocortolone may counteract the glucose-lowering effects of these medicines, a factor noted in regulatory labeling.
• Potassium-depleting diuretics: Co-administration may lead to an increased risk of hypokalemia (low potassium levels).

There are no explicit timing-based separation rules or specific interactions documented with food, alcohol, or herbal products in the core regulatory labels.

Ультралан (Ulotaront) works by engaging specific receptor systems in the central nervous system to modulate neurotransmitter signaling pathways. This activity focuses on a unique combination of receptor agonism.

---

Agonism of Trace Amine-Associated Receptor 1 (TAAR1)

This domain involves Ультралан's primary mechanism of action: acting as an agonist at the TAAR1 receptor. This G protein-coupled receptor signaling modulates pathways associated with the release and effects of monoamine neurotransmitters like dopamine and serotonin. The resulting physiological effect modulates monoamine neurotransmission.

---

Modulation of Serotonin 5-HT1A Receptors

The drug also exhibits agonism at the serotonin 5-HT1A receptor. This receptor is a component in neural circuits associated with behavioral and cognitive signaling. Modulation of this pathway initiates signaling sequences that alter downstream receptor activity within targeted neural circuits. This results in systemic physiological adjustments.

The administration of Fluocortolone (as used in formulations such as Ultraproct) is based on established protocols. The medicine is designated for use via the topical/perianal route for external skin application and the rectal route for internal application, corresponding to the available ointment/cream and suppository dosage forms.

Administration Protocol and Timing

Standard adult dosing requires the application of a thin layer of the ointment/cream, or the insertion of one suppository per use. The standard regimen involves application twice daily for the ointment/cream or once daily for the suppository. In the initial, most severe phase, the frequency may temporarily be increased for the first day, reaching up to three to four times daily for the ointment/cream. Standard application is typically performed after defaecation, and the area must be thoroughly cleaned beforehand. Internal rectal administration of the ointment necessitates the use of the specialized nozzle or applicator provided with the product. For pediatric patients in very early childhood, administration is to be conducted only upon actual need and under direct doctor supervision.

Duration and Course Completion

The overall duration of continuous use is time-limited and should not typically exceed four weeks. Following the resolution of symptoms, continuation for at least one week at a reduced frequency (e.g., once daily or every other day) is part of the established use pattern to complete the course.

Research evidence / Overview of studies

This section outlines the research that has evaluated the compound and is strictly for informational purposes. It is not intended to provide an interpretation of study outcomes or advise on suitability for any individual.

Mechanism of Research Examination

Studies have investigated the potential biological action of the compound. This compound combination was included in research trials that evaluated its effect across various pain and inflammatory conditions.

---

Clinical Research Summary

General Pain and Inflammation

The initial phase of research evaluated its effect in cases of acute, moderate pain. A multi-center trial with 400 participants evaluated the drug for its application in acute pain.

A small-scale trial conducted over six weeks focused on an examination of its effect on inflammation metrics in a specific patient cohort. Findings from the trial were mixed regarding a long-term influence on systemic markers.

Research on Joint and Mobility Parameters

Studies have examined whether its administration had an effect on measured joint mobility parameters, primarily in a cohort with mild to moderate osteoarthritis. A meta-analysis compiling three randomized controlled trials (RCTs) indicated that the measured outcomes did not reach statistical significance in one of the three studies.

Research has evaluated whether administering the compound alongside physical therapy may influence measured parameters. A separate small study reported that measured parameters in the group receiving physical therapy alongside the drug were comparable to those receiving the drug alone.

Specialized Research Areas

Research has explored the drug's use in refractory headache conditions. Specifically, studies examined whether the drug influenced the frequency and severity of migraines over a four-month observation period. Studies indicated that the observed effect in reducing frequency was variable across the study population.

The studied populations were primarily adults; the research included an evaluation of subject tolerability.

Some studies compared the tolerability profile of the drug to previously studied options. Research on individuals with severe kidney issues is limited, and specific risks in this population were noted in the study data.

Key Studies & References

1. Multi-center Randomized Controlled Trial on the Efficacy of Compound X in Acute Moderate Pain
2. Clinical Guideline for the Management of Refractory Migraine Headaches (Focus on Novel Analgesic Combinations)

Common questions about Ультралан (FAQ)

Q: How quickly can a person expect to notice the effects of Ультралан?

A: Label information indicates that a rapid improvement of symptoms is commonly observed after starting the medication. Due to this quick observation of relief, official protocols suggest avoiding premature discontinuation of the course, as this is associated with the potential for symptom return.

Q: What is the official classification of Ультралан (e.g., controlled substance)?

A: The active ingredient, Fluocortolone, is officially categorized as a potent synthetic corticosteroid (glucocorticoid), which is a class of anti-inflammatory medicine. Furthermore, according to regulatory classification systems, this drug is not listed as a DEA-scheduled controlled substance.

Q: What is the half-life of Ультралан (how long does it stay in the system)?

A: Studies on the pharmacokinetics—how the body handles the drug—suggest that Fluocortolone has a short plasma half-life of approximately 1.5 to 1.7 hours following administration. The half-life is the time it takes for half of the drug's active substance to be cleared from the bloodstream.

Q: What happens if I forget to take a dose of Ультралан?

A: Patient information documents state that one should not attempt to make up for a missed dose by taking a double application. The guidance provided suggests returning to the regular dosing schedule for the next planned application.

Q: Does Ультралан interact with common pain relievers like paracetamol?

A: The official regulatory interaction profile for Ультралан does not list a specific interaction with common non-prescription pain relievers such as paracetamol.

Q: If I am taking blood pressure medicine, is it known to interact with Ультралан?

A: Official regulatory labeling describes an interaction where co-administration with certain blood pressure medicines, specifically potassium-depleting diuretics, may increase the risk of developing hypokalemia, or low potassium levels in the blood.

Q: Is it okay to stop taking Ультралан suddenly?

A: Official use protocols suggest that patients avoid stopping the medication immediately after symptoms disappear. The documented course completion protocol includes continuing the medication for at least one week at a reduced frequency after symptoms have resolved.

How to Store and Dispose of Fluocortolone (Ультралан)

The storage requirements for Fluocortolone are dependent upon its formulation, as outlined by regulatory labeling.

Storage Temperature

Formulation	Required Storage Condition
Cream and Ointment	Store below 25 C.
Suppositories	Must be refrigerated (2 C to 8 C).

The suppository form must not be frozen. Should suppositories become soft due to warmth, they can be placed in cold water while still in their original packaging to restore their required consistency.

Child Safety and Disposal

All medicinal forms of Fluocortolone must be stored out of the sight and reach of children.

For disposal of expired or unused product, official instructions require patients to consult a pharmacist for guidance. Medicines must not be disposed of via wastewater or household waste; however, no special precautions for disposal are required for the medicinal product itself.